Industry Audit

Trombetta, Bill
September 2005
Pharmaceutical Executive;Sep2005, Vol. 25 Issue 9, p68
Trade Publication
Presents the ranking of the top ten sixteen publicly traded pharmaceutical companies in the U.S. Revenue from the 2003 global sales of prescription drugs and vaccines; Earnings per share; Assessment of the gross margin; Escalation of the productivity of three major representatives, Amgen, Genentech and Biogen. INSET: WHAT THE DUPONT LONG-TERM RETURN-ON-INVESTMENT MODEL TELLS US.


Related Articles

  • Lannett ups revenue outlook. Investor's Business Daily // Investors Business Daily;11/4/2014, pA02 

    The generic-drug maker's adjusted EPS skyrocketed 327% to 94 cents in Q1 '15, passing views by 10 cents. Revenue soared 104% to $93.4 mil, topping expectations for $91.9 mil.

  • An Empirical Study to test the Explanatory Power of the Factor Portfolios. Amit, B. Mirji // Advances in Management;Feb2013, Vol. 6 Issue 2, p15 

    The study tests whether growth in cash earnings per share (CEPS) for a portfolio is explained by similar growth in factor portfolios like market, SMB and HML as envisaged in the Fama and French three-factor return model for NSE listed companies during 1996- 2010. The results show that growth in...

  • Popular's Net Income Declines as Mortgage Securities Trading Falls.  // National Mortgage News;7/24/2006, Vol. 30 Issue 41, p18 

    The article reports on the net income of Popular Inc., a Puerto Rico-based a banking and mortgage firm for the second quarter in the U.S. The banking and mortgage firm reveals that the company's net income is decreasing as well as its earnings per share. However, there is a non-interest income...

  • Glanbia Share Earnings Boost.  // Hospitality Ireland;Feb2009, Issue 55, p77 

    The article reports on the 17% growth in adjusted earnings per share of Glanbia in 2008. Food Ingredients Ireland was the only Glanbia business that reportedly failed to perform in line with or better than the expectations. The financial condition is predicted by the company to pose more...

  • Nuts and Bolts of the BT 500.  // Business Today;11/14/2010, Vol. 19 Issue 23, p152 

    The article focuses on the developments of "Business Today" (BT) 500 that evaluate most valuable companies in India. It highlights the incorporation of two specific changes such as the earnings per share (EPS) of each companies and the broader scope. It notes that BT has relied on Prowess, a...

  • The Two-Class Stock Method for Calculating Earnings per Share. Rashty, Josef // CPA Journal;Aug2012, Vol. 82 Issue 8, p26 

    The article explains the application of the two-class method in the calculation of basic and diluted earnings per share (EPS) for stock compensation awards that are considered participating securities under Accounting Standards Codification (ASC) 260. The two-class method treats participating...

  • Teva Pharmaceutical's. Investor's Business Daily // Investors Business Daily;11/ 1/2013, pA02 

    The article reports on the financial performance of Teva Pharmaceutical in the third quarter (Q3) of 2013 including its stable earnings per share (EPS), increased revenue, and the 1% rise in the sales of its multiple sclerosis drug.

  • Walgreen has cure for slow-growth flu.  // Dow Theory Forecasts;8/8/2005, Vol. 61 Issue 32, p8 

    Highlights the business performance record of drugstore chain Walgreen Co. for 30 consecutive years leading to 2005 by emphasizing convenience to customers and capitalizing on growing demand for prescription drugs. Company history; Sales of generic drugs that have boosted recent profit gains;...

  • Don't judge a quarter by its cover.  // Dow Theory Forecasts;8/7/2006, Vol. 62 Issue 32, p1 

    The article focuses on the June-quarter review of profits which showed 69% of the 322 Standard & Poor 500 companies who declared earnings topped consensus estimates in the U.S. In an average estimate, earnings per share will be 5.3% which is said to be better compared to the 2004 earnings of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics